Rezolute Inc 2026年季度报告

Table of Contents PART I – FINANCIAL INFORMATION CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2025 (the “Report”) contains statementsreflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as “forward-lookingstatements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included orincorporated by reference in this Report, other than statements of historical fact, that address activities, events or developmentsthat we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear ina number of places, including, but not limited to “Management’s Discussion and Analysis of Financial Condition and Resultsof Operations.” These statements represent our reasonable judgment of the future based on various factors and using numerous ●our ability to obtain regulatory approvals for our therapeutics in development; ●our expectations regarding clinical development and the timeline to complete clinical studies; ●our projected operating or financial results, including anticipated cash flows to be used in operating activities; ●our expectations regarding capital expenditures, research and development (“R&D”) expenses and the timing ofmilestone payments required under license agreements; ●our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing;●our future dependence on third-party manufacturers or strategic partners to manufacture any of our pharmaceuticaldrugs and diagnostics that receive regulatory approval; and●our ability to identify strategic partners and enter into license, co-development, collaboration or similar arrangements. Any or all of our forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or byknown and unknown risks, uncertainties and other factors including, but not limited to, the risks described in Part II, Item 1A.Risk Factors, of this Report as well as “Risk Factors” described in Part I, Item 1A of our Annual Report on Form 10-K for the In addition, there may be other factors that could cause our actual results to be materially different from the results referencedin the forward-looking statements, some of which are included elsewhere in this Report, including “Management’s Discussionand Analysis of Financial Condition and Results of Operations.” Many of these factors will be important in determining ourfuture results. Consequently, no forward-looking statement can be guaranteed. Our future results may vary materially fromthose expressed or implied in any forward-looking statements. All forward-looking statements contained in this Report are PARTI– FINANCIAL INFORMATION Rezolute,Inc. Rezolute,Inc. Notesto Unaudited Condensed Consolidated Financial Statements Note 1 — Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Rezolute, Inc. (the “Company”) is a late-stage rare disease company focused on significantly improving outcomes forindividuals with hypoglycemia caused by hyperinsulinism (“HI”). The Company’s primary clinical asset, ersodetug, is apotential treatment that the Company believes could be a treatment for all forms of HI, including congenital HI and tumor HI.The Company is currently enrolling in a Phase 3 clinical trial for a tumor HI indication (“upLIFT”). In December 2025, the Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principlesgenerally accepted in the United States of America (“GAAP”), and the rules and regulations of the SEC for interim financial The condensed consolidated balance sheet as of June 30, 2025, has been derived from the Company’s audited consolidatedfinancial statements. The unaudited interim financial statements should be read in conjunction with the 2025 Form 10-K, whichcontains the Company’s audited financial statements and notes thereto, together with Management’s Discussion and Analysis The Company’s Chief Executive Officer also serves as the Company’s chief operating decision maker (“CODM”) for purposesof allocating resources and assessing performance based on financial information of the Company. Since its inception, the Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAPhave been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly,the interim financial statements do not include all information and footnote disclosures necessary for a comprehensivepresentation of financial position, results of operations, and cash flows. It is management’s opinion, however, that all material Consolidation The Company has two wholly owned subsidiaries consisting of Rezolute